ARTELO BIOSC. NEW DL-,001

Artelo Biosciences presents preclinical results showing that the FATP5 inhibitor ART26.12 reduced oral osteoarthritis pain after acute and chronic administration over four weeks and achieved efficacy comparable to naproxen. In animal studies the compound caused fewer gastric tissue lesions than naproxen, and different effects on endocannabinoids and bioactive lipids were observed. The company plans a clinical dose-escalation study to assess safety, tolerability and pharmacokinetics, with recruitment expected to start in the fourth quarter. » More on de.investing.com

Artelo Biosciences presented positive phase‑1 results for the orally administered FABP5 inhibitor ART26.12 at the International Cannabinoid Research Society symposium. The drug was well tolerated across all dose levels, showed linear pharmacokinetics and reached plasma concentrations above the preclinically predicted therapeutic thresholds. There is a wide safety margin between therapeutic exposure and the maximum tolerated dose. The company is also investigating AI‑driven biomarker signatures to further develop the candidate, which is being developed as a non‑opioid, non‑steroidal analgesic for chemotherapy‑induced peripheral neuropathy. » More on de.investing.com

Artelo has launched a strategic collaboration with bio-AI company ScienceMachine to accelerate the development of its FABP5 inhibitors, notably ART26.12. The AI platform analyzes Artelo’s FABP datasets and identified potential protein and lipid signatures that correlate with dose-dependent analgesic effects and biomarkers for response to FABP5. Preliminary results from a psoriasis model are expected to be published later this year. The stock trades at $3.77 with a market capitalization of around $3.5 million, after the share price fell 79% last year. » More on de.investing.com